You need JavaScript to view this

Pharmacological treatment of the benign prostatic hyperplasia; Tratamiento farmacologico en la hiperplasia prostatica benigna

Journal Article:

Abstract

Benign prostatic hyperplasia is a common disease in over 50 years-old men consisting in uncontrolled and benign growth of prostatic gland that leads to lower urinary tract symptoms. The etiology of benign prostatic hyperplasia is multifactoral involving the increased conversion of testosterone in dihydrotestosterone by the prostatic 5{alpha}-reductase action, which brought about events that encourage the prostate growth (static component) and the increase of the bladder and prostate smooth muscle tone (dynamic component) regulated by the a{alpha}{sub 1} -adrenoceptors (ADR). The pharmacological treatment of the benign prostatic hyperplasia includes the prostatic 5a{alpha}-reductase inhibitors, the a{alpha}{sub 1}-adrenoreceptor blockers, their combined therapy and the phytotherapy. This paper was aimed at presenting the most relevant aspects of the pharmacology of drugs used for treating the benign prostatic hyperplasia, and providing elements to analyze their efficacy, safety and tolerability. To this end, a review was made of the different drugs for the treatment of this pathology and they were grouped according to their mechanism of action. Natural products were included as lipid extracts from Serenoa repens and Pygeum africanum as well as D-004, a lipid extract from Roystonea regia fruits, with proved beneficial effects on the main etiological factors of benign prostatic hyperplasia. D-004  More>>
Authors:
Perez Guerra, Yohani; Molina Cuevas, Vivian; Oyarzabal Yera, Ambar; Mas Ferreiro, Rosa, E-mail: yohani.perez@cnic.edu.c [1] 
  1. Centro de Productos Naturales, Centro Nacional de Investigaciones Cientificas (CNIC), La Habana (Cuba)
Publication Date:
Jul 01, 2011
Product Type:
Journal Article
Resource Relation:
Journal Name: Revista Cubana de Farmacia (Online); Journal Volume: 45; Journal Issue: 1
Subject:
62 RADIOLOGY AND NUCLEAR MEDICINE; ANTIOXIDANTS; COMBINED THERAPY; LIPIDS; MEN; PHARMACOLOGY; PROSTATE; TESTOSTERONE; ANDROGENS; ANDROSTANES; ANIMALS; BODY; GLANDS; HORMONES; HYDROXY COMPOUNDS; KETONES; MALE GENITALS; MALES; MAMMALS; MAN; MEDICINE; ORGANIC COMPOUNDS; ORGANS; PRIMATES; STEROID HORMONES; STEROIDS; THERAPY; VERTEBRATES
OSTI ID:
21516176
Country of Origin:
Cuba
Language:
Spanish
Other Identifying Numbers:
Journal ID: ISSN 1561-2988; TRN: CU1100131106141
Availability:
Also available on line at the web site http://bvs.sld.cu/revistas/far/vol45_1_11/far12111.htm
Submitting Site:
INIS
Size:
vp.
Announcement Date:
Dec 29, 2011

Journal Article:

Citation Formats

Perez Guerra, Yohani, Molina Cuevas, Vivian, Oyarzabal Yera, Ambar, and Mas Ferreiro, Rosa, E-mail: yohani.perez@cnic.edu.c. Pharmacological treatment of the benign prostatic hyperplasia; Tratamiento farmacologico en la hiperplasia prostatica benigna. Cuba: N. p., 2011. Web.
Perez Guerra, Yohani, Molina Cuevas, Vivian, Oyarzabal Yera, Ambar, & Mas Ferreiro, Rosa, E-mail: yohani.perez@cnic.edu.c. Pharmacological treatment of the benign prostatic hyperplasia; Tratamiento farmacologico en la hiperplasia prostatica benigna. Cuba.
Perez Guerra, Yohani, Molina Cuevas, Vivian, Oyarzabal Yera, Ambar, and Mas Ferreiro, Rosa, E-mail: yohani.perez@cnic.edu.c. 2011. "Pharmacological treatment of the benign prostatic hyperplasia; Tratamiento farmacologico en la hiperplasia prostatica benigna." Cuba.
@misc{etde_21516176,
title = {Pharmacological treatment of the benign prostatic hyperplasia; Tratamiento farmacologico en la hiperplasia prostatica benigna}
author = {Perez Guerra, Yohani, Molina Cuevas, Vivian, Oyarzabal Yera, Ambar, and Mas Ferreiro, Rosa, E-mail: yohani.perez@cnic.edu.c}
abstractNote = {Benign prostatic hyperplasia is a common disease in over 50 years-old men consisting in uncontrolled and benign growth of prostatic gland that leads to lower urinary tract symptoms. The etiology of benign prostatic hyperplasia is multifactoral involving the increased conversion of testosterone in dihydrotestosterone by the prostatic 5{alpha}-reductase action, which brought about events that encourage the prostate growth (static component) and the increase of the bladder and prostate smooth muscle tone (dynamic component) regulated by the a{alpha}{sub 1} -adrenoceptors (ADR). The pharmacological treatment of the benign prostatic hyperplasia includes the prostatic 5a{alpha}-reductase inhibitors, the a{alpha}{sub 1}-adrenoreceptor blockers, their combined therapy and the phytotherapy. This paper was aimed at presenting the most relevant aspects of the pharmacology of drugs used for treating the benign prostatic hyperplasia, and providing elements to analyze their efficacy, safety and tolerability. To this end, a review was made of the different drugs for the treatment of this pathology and they were grouped according to their mechanism of action. Natural products were included as lipid extracts from Serenoa repens and Pygeum africanum as well as D-004, a lipid extract from Roystonea regia fruits, with proved beneficial effects on the main etiological factors of benign prostatic hyperplasia. D-004 is a prostatic 5a-reductase inhibitor, an a{alpha}{sub 1}-adrenoceptor antagonist, a{alpha} 5-lipooxygenase inhibitor and has antioxidant action, all of which reveals a multifactoral mechanism. The results achieved till now indicate that D-004 is a safe and well-tolerated product}
journal = {Revista Cubana de Farmacia (Online)}
issue = {1}
volume = {45}
place = {Cuba}
year = {2011}
month = {Jul}
}